Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (241-250 of 323) with videos related to

Pageof 33
Sort By:
Advances in Therapy|October 10, 2020
Adherence to the EAU Guideline Recommendations for Local Tumor Treatment in Penile Cancer: Results of the European PROspective Penile Cancer Study Group Survey (E-PROPS)Maximilian Pallauf, Marie C Hempel, Marie C Hupe, et al.
Future Oncology (London, England)|January 17, 2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Joan Carles, et al.
European Urology|October 29, 2015
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted TherapyThomas Powles, Michael Staehler, Börje Ljungberg, et al.
International Journal of Molecular Sciences|November 11, 2022
The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone MicroenvironmentAlireza Saraji, Kang Duan, Christian Watermann, et al.
European Urology|December 18, 2016
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell CarcinomaAxel Bex, Laurence Albiges, Börje Ljungberg, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
Nature Reviews. Urology|January 4, 2023
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutationsPawel Rajwa, Fahad Quhal, Benjamin Pradere, et al.
JAMA Oncology|June 28, 2019
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 StudyGerhardt Attard, Axel S Merseburger, Wiebke Arlt, et al.
The Journal of Urology|May 22, 2019
Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGADaley S Morera, Sarrah L Hasanali, Daniel Belew, et al.
European Urology|June 29, 2016
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted TherapyThomas Powles, Michael Staehler, Börje Ljungberg, et al.
Pageof 33

Showing results (241-250 of 323) with videos related to

Sort By:
Pageof 33
Advances in Therapy|October 10, 2020
Adherence to the EAU Guideline Recommendations for Local Tumor Treatment in Penile Cancer: Results of the European PROspective Penile Cancer Study Group Survey (E-PROPS)Maximilian Pallauf, Marie C Hempel, Marie C Hupe, et al.
Future Oncology (London, England)|January 17, 2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Joan Carles, et al.
European Urology|October 29, 2015
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted TherapyThomas Powles, Michael Staehler, Börje Ljungberg, et al.
International Journal of Molecular Sciences|November 11, 2022
The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone MicroenvironmentAlireza Saraji, Kang Duan, Christian Watermann, et al.
European Urology|December 18, 2016
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell CarcinomaAxel Bex, Laurence Albiges, Börje Ljungberg, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
Nature Reviews. Urology|January 4, 2023
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutationsPawel Rajwa, Fahad Quhal, Benjamin Pradere, et al.
JAMA Oncology|June 28, 2019
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 StudyGerhardt Attard, Axel S Merseburger, Wiebke Arlt, et al.
The Journal of Urology|May 22, 2019
Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGADaley S Morera, Sarrah L Hasanali, Daniel Belew, et al.
European Urology|June 29, 2016
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted TherapyThomas Powles, Michael Staehler, Börje Ljungberg, et al.
Pageof 33